What does PREMIUM PHARMA do?

PREMIUM PHARMA is an events organiser in Elsene. Private Limited, started on 12 March 2008, 2 establishments.

What is the address of PREMIUM PHARMA?

The registered office of PREMIUM PHARMA is located at Louizalaan 163, 1050 Elsene.

Is PREMIUM PHARMA still active?

Yes. According to the CBE (31 October 2026) PREMIUM PHARMA is active, legal situation “Normale toestand”, started on 12 March 2008.

Is PREMIUM PHARMA registered on Peppol?

Yes, PREMIUM PHARMA is registered on the Peppol network with ID 0208:0896401843.

What is the enterprise number of PREMIUM PHARMA?

The enterprise number of PREMIUM PHARMA is BE0896401843.

When was PREMIUM PHARMA founded?

PREMIUM PHARMA was founded on 12 March 2008.

Who are the directors of PREMIUM PHARMA?

According to the 2025 annual accounts, the directors of PREMIUM PHARMA are: Olivier Lebbink.

Is PREMIUM PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 March 2008; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did PREMIUM PHARMA make in 2025?

PREMIUM PHARMA recorded a loss after taxes of € 15,104 in financial year 2025.

What is the revenue of PREMIUM PHARMA?

As a small company, PREMIUM PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -9,664.

PREMIUM PHARMA (Private Limited) - Elsene - BE0896401843

Dossier PREMIUM PHARMA, printed on 1 November 2026 from databakkes.be/en/0896401843/premium-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 34 % of short-term debt in 2025; threshold 65 %.
Busy address KBO

53 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

PREMIUM PHARMA from Elsene, company number BE0896401843, closed financial year 2025 with a result of € -15,104 after tax. For that financial year PREMIUM PHARMA recorded a gross margin of € -9,664 and equity of € 2,501. Compared with financial year 2024, the result moved from € 24,667 to € -15,104. The company made a loss. The buffer shrank hard: equity is 86 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.

What it is worth Shrank hard

€ 2,501

▼ 86% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -15,104

▼ still € 24,667 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1,461

▲ € 1,128 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -16,099.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost estimate Staff cost at a one-person company Staff Only people on the payroll count here.€ 20 Likely the director’s social contribution or pension premium.The director’s pay Already netted into the gross margin, not shown separately in the accounts. Typical for one-person companies € 45,000 gross per year minimum for the reduced tax rate≈ € 2,100 net per month after contributions, tax and usually some benefits in kind, roughly Assumption based on the chart of accounts, not a figure from the source.

€ 20

▼ € 62,335 vs 2024

No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.

Vehicles and equipment

€ 608

▼ 32% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 52,137

▼ 25% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 765

▼ 24% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 23,162 Gross margin 2022: € 23,162 First fiscal year in the series	€ 22,576 Gross margin 2023: € 22,576 ▼ 3% vs 2022 (€ 23,162) Unfavourable step	€ 99,952 Gross margin 2024: € 99,952 ▲ € 77,375 vs 2023 (€ 22,576) Favourable step	€ -9,664 Gross margin 2025: € -9,664 ▼ € 109,616 vs 2024 (€ 99,952) Unfavourable step	▼ € 109,616
Profit after taxes	€ 443 Profit after taxes 2022: € 443 First fiscal year in the series	€ -40,178 Profit after taxes 2023: € -40,178 ▼ € 40,621 vs 2022 (€ 443) Unfavourable step	€ 24,667 Profit after taxes 2024: € 24,667 ▲ € 64,844 vs 2023 (€ -40,178) Favourable step	€ -15,104 Profit after taxes 2025: € -15,104 ▼ € 39,770 vs 2024 (€ 24,667) Unfavourable step	▼ € 39,770
Equity	€ 33,116 Equity 2022: € 33,116 First fiscal year in the series	€ -7,062 Equity 2023: € -7,062 ▼ € 40,178 vs 2022 (€ 33,116) Unfavourable step	€ 17,605 Equity 2024: € 17,605 ▲ € 24,667 vs 2023 (€ -7,062) Favourable step	€ 2,501 Equity 2025: € 2,501 ▼ 86% vs 2024 (€ 17,605) Unfavourable step	▼ 86%
Total debts	€ 260,942 Total debts 2022: € 260,942 First fiscal year in the series	€ 256,784 Total debts 2023: € 256,784 ▼ 2% vs 2022 (€ 260,942) Favourable step	€ 70,594 Total debts 2024: € 70,594 ▼ 73% vs 2023 (€ 256,784) Favourable step	€ 53,352 Total debts 2025: € 53,352 ▼ 24% vs 2024 (€ 70,594) Favourable step	▼ 24%
Cash	€ 44,197 Cash 2022: € 44,197 First fiscal year in the series	€ 5,969 Cash 2023: € 5,969 ▼ 86% vs 2022 (€ 44,197) Unfavourable step	€ 333 Cash 2024: € 333 ▼ 94% vs 2023 (€ 5,969) Unfavourable step	€ 1,461 Cash 2025: € 1,461 ▲ € 1,128 vs 2024 (€ 333) Favourable step	▲ € 1,128
Land & buildings	€ 75,600 Land & buildings 2022: € 75,600 First fiscal year in the series	€ 72,000 Land & buildings 2023: € 72,000 ▼ 5% vs 2022 (€ 75,600) Unchanged	-	-
Retained profit	€ 14,516 Retained profit 2022: € 14,516 First fiscal year in the series	€ -25,662 Retained profit 2023: € -25,662 ▼ € 40,178 vs 2022 (€ 14,516) Unfavourable step	€ -995 Retained profit 2024: € -995 ▲ € 24,667 vs 2023 (€ -25,662) Favourable step	€ -16,099 Retained profit 2025: € -16,099 ▼ € 15,104 vs 2024 (€ -995) Unfavourable step	▼ € 15,104
Bank debt	€ 168,064 Bank debt 2022: € 168,064 First fiscal year in the series	€ 129,037 Bank debt 2023: € 129,037 ▼ 23% vs 2022 (€ 168,064) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 129,037) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 294,058 Balance sheet total 2022: € 294,058 First fiscal year in the series	€ 249,722 Balance sheet total 2023: € 249,722 ▼ 15% vs 2022 (€ 294,058) Unchanged	€ 88,198 Balance sheet total 2024: € 88,198 ▼ 65% vs 2023 (€ 249,722) Unchanged	€ 55,853 Balance sheet total 2025: € 55,853 ▼ 37% vs 2024 (€ 88,198) Unchanged	▼ 37%

Key figures of PREMIUM PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PREMIUM PHARMA?

What happened at PREMIUM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 29, 2026 New annual accounts for financial year 2025: loss of € 15,104 (▼ € 39,770 vs 2024). filed late Source: NBB ↗
May 1, 2015 New establishment in Zaventem. KBO
May 6, 2008 New establishment in Elsene. KBO
Mar 12, 2008 Start of the company according to the CBE. KBO

In short

From € 443 profit in 2022 to € 15,104 loss in 2025.

Paid € 2,314 in corporate taxes since 2022.

Best year ever: 2024, with € 24,667 profit.

Original PDFs at the National Bank ↗

Management

Olivier Lebbink

PREMIUM PHARMA

PREMIUM CONSULTING & MANAGEMENT

PREMIUM PHARMA RETAIL

Behind PREMIUM PHARMA is Olivier Lebbink. Olivier Lebbink is also behind PREMIUM CONSULTING & MANAGEMENT and PREMIUM PHARMA RETAIL.

Directors

According to the 2025 annual accounts

Olivier Lebbink

Director

Also active at: PREMIUM CONSULTING & MANAGEMENT, PREMIUM PHARMA RETAIL

Establishments

Establishment units

Physical locations of this company

Registered office

Louizalaan 163

1050 Elsene

2.241.887.556

Excelsiorlaan 61

1930 Zaventem

Active since 1 May 2015

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 53 companies are registered at this address.

All companies at this address →

Triple S Plus

TALBI

€ 25,728 gross margin · 2024

GARSIAL TRADE

€ -2,313 gross margin · 2025

FESCACOM IT

€ 33,848 gross margin · 2025

FLAVES

€ 30,643 gross margin · 2024

+48 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0896.401.843

VAT number

BE 0896.401.843

Registered office

Louizalaan 163, 1050 Elsene

Names & denominations

PREMIUM PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

12 March 2008

Peppol

Active · Active since 23 Aug 2024

Activities · NACE

Organisatie van congressen en beurzen

Administratieve en ondersteunende activiteiten ten behoeve van kantoren

Arbeidsbemiddeling

Beroepsopleiding

Activiteiten van reclamebureaus

Diverse administratieve activiteiten ten behoeve van kantoren

Fotokopiëren, documentvoorbereiding en andere gespecialiseerde ondersteunende activiteiten ten behoeve van kantoren

View on CBE Public ↗ Annual accounts (NBB) ↗

PREMIUM PHARMA

Warning lights

Financials

What happened to PREMIUM PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions